As of 2013, thalassemia occurs in about 280 million people, with about 439,000 having severe disease.
, and African descent.
Males and females have similar rates of disease.
It resulted in 16,800 deaths in 2015, down from 36,000 deaths in 1990.
, explaining why they are more common in regions of the world where malaria exists.
Both α- and β-thalassemias are often inherited in an
autosomal recessive manner. Cases of
dominantly inherited α- and β-thalassemias have been reported, the first of which was in an Irish family with two deletions of 4 and 11 bp in exon 3 interrupted by an insertion of 5 bp in the β-globin gene. For the autosomal recessive forms of the disease, both parents must be carriers for a child to be affected. If both parents carry a hemoglobinopathy trait, the risk is 25% for each pregnancy for an affected child.
EvolutionEdit
Normally, the majority of adult hemoglobin (
HbA) is composed of four protein chains, two α and two β globin chains arranged into a
heterotetramer. In thalassemia, patients have defects in either the α or β globin chain, causing production of abnormal red blood cells (In
sickle-cell disease, the mutation is specific to β globin).
The thalassemias are classified according to which chain of the hemoglobin molecule is affected. In
α-thalassemias, production of the α globin chain is affected, while in
β-thalassemia, production of the β globin chain is affected.
The β globin chains are encoded by a single gene on
chromosome 11; α globin chains are encoded by two closely linked genes on
chromosome 16.
[21] Thus, in a normal person with two copies of each chromosome, two loci encode the β chain, and four loci encode the α chain. Deletion of one of the α loci has a high prevalence in people of African or Asian descent, making them more likely to develop
α-thalassemia.
β-Thalassemias are not only common in
Africans, but also in
Greeks and
Italians.
Alpha-thalassemiasEdit
The α-thalassemias involve the genes
HBA1[22] and
HBA2,
[23] inherited in a
Mendelian recessive fashion. Two
gene lociand so four alleles exist. It is also connected to the deletion of the 16p chromosome. α Thalassemias result in decreased alpha-globin production, therefore fewer alpha-globin chains are produced, resulting in an excess of β chains in adults and excess γ chains in newborns. The excess β chains form unstable tetramers (called hemoglobin H or HbH of 4 beta chains), which have abnormal oxygen dissociation curves.
Beta-thalassemiaEdit
Beta thalassemias are due to mutations in the
HBB gene on chromosome 11,
[24] also inherited in an autosomal, recessive fashion. The severity of the disease depends on the nature of the mutation and on the presence of mutations in one or both alleles.
Mutated alleles are called β
+ when partial function is conserved (either the protein has a reduced function, or it functions normally but is produced in reduced quantity) or β
o, when no functioning protein is produced.
The situation of both alleles determines the clinical picture:
- β thalassemia major (Mediterraneananemia or Cooley anemia) is caused by a βo/βo genotype. No functional β chains are produced, and thus no hemoglobin A can be assembled. This is the most severe form of β-thalassemia;
- β thalassemia intermedia is caused by a β+/βo or β+/β+ genotype. In this form, some hemoglobin A is produced;
- β thalassemia minor is caused by a β/βo or β/β+ genotype. Only one of the two β globin alleles contains a mutation, so β chain production is not terribly compromised and patients may be relatively asymptomatic.
Delta-thalassemiaEdit
As well as alpha and beta chains present in hemoglobin, about 3% of adult hemoglobin is made of alpha and delta chains. Just as with beta thalassemia, mutations that affect the ability of this gene to produce delta chains can occur.
[citation needed]
Combination hemoglobinopathiesEdit
A screening policy exists in
Cyprus to reduce the rate of thalassemia, which, since the program's implementation in the 1970s (which also includes prenatal screening and abortion), has reduced the number of children born with the disease from one of every 158 births to almost zero.
[27] Greece also has a screening program to identify people who are carriers.
[28]
Large scale awareness campaigns are being organized in
India[30] both by government and non-government organizations in favor of voluntary premarital screening to detect carriers of thalassemia and marriage between both carriers are strongly discouraged.
Mild thalassemia: people with thalassemia
traits do not require medical or follow-up care after the initial diagnosis is made.
[31] People with β-thalassemia trait should be warned that their condition can be misdiagnosed as the more common
iron deficiency anemia. They should avoid routine use of
iron supplements; iron deficiency can develop, though, during pregnancy or from chronic bleeding.
[32] Counseling is indicated in all persons with genetic disorders, especially when the family is at risk of a severe form of disease that may be prevented.
[33]
People with severe thalassemia require medical treatment. A blood transfusion regimen was the first measure effective in prolonging life.
[31]
Iron overloadEdit
Multiple blood transfusions can result in iron overload. The iron overload related to thalassemia may be treated by
chelation therapy with the medications
deferoxamine,
deferiprone, or
deferasirox.
[34] These treatments have resulted in improving life expectancy in those with thalassemia major.
[34]
Deferoxamine is only effective via daily injections which makes its long-term use more difficult. It has the benefit of being inexpensive and decent long-term safety. Adverse effects are primary skin reactions around the injection site and
hearing loss.
[34]
Deferasirox has the benefit of being an oral medication. Common side effects include: nausea, vomiting and diarrhea. It however is not effective in everyone and is probably not suitable in those with significant cardiac issues related to iron overload. The cost is also significant.
[34]
Deferiprone is a medication that is given by mouth. Nausea, vomiting, and diarrhea are relatively common with its use.
[34] It is available in both Europe and the United States.
[34][35] It appears to be the most effective agent when the heart is significantly involved.
[34]
Bone marrow transplantationEdit
Bone marrow transplantation may offer the possibility of a cure in young people who have an
HLA-matched donor.
[37] Success rates have been in the 80–90% range.
[37] Mortality from the procedure is about 3%.
[38] There are no randomized controlled trials which have tested the safety and efficacy of
non-identical donor bone marrow transplantation in persons with β- thalassemia who are dependent on blood transfusion.
[39]
If the person does not have an HLA-matched compatible donor, another method called bone marrow transplantation (BMT) from haploidentical mother to child (mismatched donor) may be used. In a study of 31 people, the thalassemia-free survival rate 70%, rejection 23%, and mortality 7%. The best results are with very young people.
[40]
The beta form of thalassemia is particularly prevalent among
Mediterranean peoples, and this geographical association is responsible for its original name.
[41] Thalassemia resulted in 25,000 deaths in 2013 down from 36,000 deaths in 1990.
[11]
In Europe, the highest concentrations of the disease are found in
Greece, coastal regions in
Turkey (particularly the
Aegean Regionsuch as
Izmir,
Balikesir,
Aydin,
Mugla, and
Mediterranean Region such as
Antalya,
Adana,
Mersin), in parts of
Italy, particularly
southern Italy and the lower Po valley. The major Mediterranean islands (except the
Balearics) such as
Sicily,
Sardinia,
Malta,
Corsica,
Cyprus, and
Crete are heavily affected in particular. Other Mediterranean people, as well as those in the vicinity of the Mediterranean, also have high rates of thalassemia, including people from
West Asiaand
North Africa. Far from the Mediterranean,
South Asians are also affected, with the world's highest concentration of carriers (30% of the population) being in the
Maldives.
Nowadays, it is found in populations living in Africa, the Americas, and in
Tharu people in the
Terai region of
Nepal and
India.
[42] It is believed to account for much lower malaria sicknesses and deaths,
[43] accounting for the historic ability of Tharus to survive in areas with heavy malaria infestation, where others could not. Thalassemias are particularly associated with people of Mediterranean origin, Arabs (especially
Palestinians and people of Palestinian descent), and Asians.
[44]The Maldives has the highest incidence of thalassemia in the world with a carrier rate of 18% of the population. The estimated prevalence is 16% in people from
Cyprus, 1%
[45] in
Thailand, and 3–8% in populations from
Bangladesh,
China,
India,
Malaysia and
Pakistan. Thalassemias also occur in descendants of people from Mediterranean countries (e.g. Greece, Italy,
Spain, and others), in
Latin America.
Estimates suggest that approximately 1.5% of the global population (80 - 90 million people) are β-thalassemia carriers.
[46] However, exact data on carrier rates in many populations are lacking, particularly in developing areas of the world known or expected to be heavily affected.
[47][48] Because of the prevalence of the disease in countries with little knowledge of thalassemia, access to proper treatment and diagnosis can be difficult.
[49] While there are some diagnostic and treatment facilities in developing countries, in most cases these are not provided by government services, and are available only to patients that can afford them. In general, poorer populations only have access to limited diagnostic facilities together with blood transfusions. In some developing countries, there are virtually no facilities for diagnosis or management of thalassemia.
[49]
The word
thalassemia (
) derives from the
Greek thalassa (θάλασσα), "sea", and
New Latin -emia (from Greek
haema (αἷμα), "blood"). It was coined because the condition called "Mediterranean anemia" was first
described in people of
Mediterraneanethnicities. "Mediterranean anemia" was renamed
thalassemia major once the genetics were better understood. The word
thalassemia was first used in 1932.
[41]:877[50]
In 2008, in Spain, a baby was
selectively implanted to be
a cure for his brother's thalassemia. The child was born from an embryo screened to be free of the disease before implantation with
in vitro fertilization. The baby's supply of immunologically compatible cord blood was saved for transplantation to his brother. The transplantation was considered successful.
[51] In 2009, a group of doctors and specialists in
Chennai and
Coimbatoreregistered the successful treatment of thalassemia in a child using an unaffected sibling's umbilical cord blood.
[52]
Gene therapyEdit
Gene therapy is being studied for thalassemia.
[53] The procedure involves collecting
hematopoietic stem cells (HSCs) from the affected person's blood. The HSCs then have a beta-globin gene added using a
lentiviral vector. After destroying the affected person's bone marrow with a dose of chemotherapy (a myeloablative conditioning regimen), the altered HSCs are infused back into the affected person where they become engrafted in the bone marrow where they proliferate. This potentially results in a progressive increase in hemoglobin A2 synthesis in all subsequent developing red blood cells, with resultant resolution of the anemia.
[54]
While one person with beta thalassemia has no longer required blood transfusions following treatment within a research trial, it is not an approved treatment as of 2018.
[53][55]
HbF inductionEdit